Aller au contenu principal

 Articles scientifiques

Tumor biology reflected by histological growth pattern is more important than surgical margin for the prognosis of patients undergoing resection of colorectal liver metastases.

Auteurs : Bohlok A, Inchiostro L, Lucidi V, Vankerckhove S, Hendlisz A, Van Laethem JL, Craciun L, Demetter P, Larsimont D, Dirix L, Vermeulen P, Donckier V
Année : 2023
Journal : Eur J Surg Oncol
Volume : 49
Pages : 217-224

ASO Visual Abstract: The Prognostic Value of Distinct Histological Growth Patterns of Colorectal Peritoneal Metastases-A Pilot Study.

Auteurs : El Asmar A, Demetter P, Fares F, Sclafani F, Hendlisz A, Donckier V, Vermeulen P, Liberale G
Année : 2023
Journal : Ann Surg Oncol

Pre-existing evidence and outcome of phase III trials in gastrointestinal oncology: a systematic review.

Auteurs : Bregni G, Trevisi E, Saude Conde R, Vanhooren M, Akin Telli T, Assaf I, Hendlisz A, Di Maio M, Sclafani F
Année : 2023
Journal : J Natl Cancer Inst

The Prognostic Value of Distinct Histological Growth Patterns of Colorectal Peritoneal Metastases: A Pilot Study.

Auteurs : El Asmar A, Demetter P, Fares F, Sclafani F, Hendlisz A, Donckier V, Vermeulen P, Liberale G
Année : 2023
Journal : Ann Surg Oncol

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.

Auteurs : Lenz HJ, van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, García-Alfonso P, Neyns B, Luppi G, Cardin DB, Dragovich T, Shah U, Abdullaev S, Gricar J, Ledeine JM, Overman MJ, Lonardi S
Année : 2022
Journal : J Clin Oncol
Volume : 40
Pages : 161-170

Combined Metabolically Active Tumor Volume and Early Metabolic Response Improve Outcome Prediction in Metastatic Colorectal Cancer.

Auteurs : Woff E, Salvatore L, Marmorino F, Genovesi D, Critchi G, Guiot T, Ameye L, Sclafani F, Hendlisz A, Flamen P
Année : 2022
Journal : J Nucl Med
Volume : 63
Pages : 549-555

JCOG0603: Are We Really Sure This Was a Negative Trial?

Auteurs : Saude Conde R, Bregni G, Saad E, Hendlisz A, Sclafani F
Année : 2022
Journal : J Clin Oncol
Volume : 40
Pages : 803-805

Results of a single-arm pilot study of (32)P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy.

Auteurs : Ross PJ, Wasan HS, Croagh D, Nikfarjam M, Nguyen N, Aghmesheh M, Nagrial AM, Bartholomeusz D, Hendlisz A, Ajithkumar T, Iwuji C, Wilson NE, Turner DM, James DC, Young E, Harris MT
Année : 2022
Journal : ESMO Open
Volume : 7
Pages : 100356

Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance.

Auteurs : Kehagias P, Kindt N, Krayem M, Najem A, Agostini G, Acedo Reina E, Bregni G, Sclafani F, Journe F, Awada A, Ghanem GE, Hendlisz A
Année : 2022
Journal : Cells
Volume : 11

Editorial: 'All you need is immunotherapy': a new treatment paradigm in sight for early-stage, mismatch repair-deficient/microsatellite instability high gastrointestinal cancers?

Auteurs : Sclafani F, Hendlisz A
Année : 2022
Journal : Curr Opin Oncol
Volume : 34
Pages : 379-381

Mind the target: human epidermal growth factor receptor 2 in colorectal cancer.

Auteurs : Saude Conde R, Rasschaert G, Bregni G, Hendlisz A, Sclafani F
Année : 2022
Journal : Curr Opin Oncol
Volume : 34
Pages : 382-388

Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer.

Auteurs : Akin Telli T, Bregni G, Vanhooren M, Saude Conde R, Hendlisz A, Sclafani F
Année : 2022
Journal : Cancer Treat Rev
Volume : 110
Pages : 102460

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.

Auteurs : André T, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Abdullaev S, Memaj A, Lei M, Dixon M, Kopetz S, Overman MJ
Année : 2022
Journal : Ann Oncol
Volume : 33
Pages : 1052-1060

Circulating DNA in the neoadjuvant setting of early stage colon cancer.

Auteurs : Bregni G, Pretta A, Senti C, Acedo Reina E, Vandeputte C, Trevisi E, Gkolfakis P, Kehagias P, Deleporte A, Van Laethem JL, Vergauwe P, Van den Eynde M, Deboever G, Janssens J, Demolin G, Holbrechts S, Clausse M, De Grez T, Peeters M, DHondt L, Geboes K, Besse-Hammer T, Rothé F, Flamen P, Hendlisz A, Sclafani F
Année : 2022
Journal : Acta Oncol
Volume : 61
Pages : 1223-1229

Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma.

Auteurs : Bouchart C, Engelholm JL, Closset J, Navez J, Loi P, Gökburun Y, De Grez T, Mans L, Hendlisz A, Bali MA, Eisendrath P, Van Gestel D, Hein M, Moretti L, Van Laethem JL
Année : 2021
Journal : Ther Adv Med Oncol
Volume : 13
Pages : 17588359211045860

Targeted agents in older patients with gastrointestinal cancers - An overview.

Auteurs : Monteiro AR, Conde RS, Basto R, Sclafani F, Deleporte A, Hendlisz A, Dal Lago L
Année : 2021
Journal : J Geriatr Oncol
Volume : 12
Pages : 1240-1252

The histological growth pattern and the clinico-metabolic characteristics accurately predict the outcome in patients undergoing surgery for colorectal liver metastases - Belgian Group for Digestive Oncology (BGDO).

Auteurs : Bohlok A, Derijckere ID, Azema H, Lucidi V, Vankerckhove S, Hendlisz A, Laethem JLV, Goldman S, Flamen P, Larsimont D, Demetter P, Dirix L, Vermeulen P, Donckier V
Année : 2021
Journal : Ann Hepatobiliary Pancreat Surg
Volume : 25
Pages : S63

Buschke-Löwenstein tumor in a human immunodeficiency virus-positive patient: a case report and short literature review.

Auteurs : Ledouble V, Sclafani F, Hendlisz A, Gomez Galdon M, Liberale G
Année : 2021
Journal : Acta Gastroenterol Belg
Volume : 84
Pages : 343-345

Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study.

Auteurs : Deleporte A, Van den Eynde M, Forget F, Holbrechts S, Delaunoit T, Houbiers G, Kalantari HR, Laurent S, Vanderstraeten E, De Man M, Vergauwe P, Clausse M, Van Der Auwera J, DHondt L, Pierre P, Ghillemijn B, Covas A, Paesmans M, Ameye L, Awada A, Sclafani F, Hendlisz A
Année : 2021
Journal : Cancer Med
Volume : 10
Pages : 4366-4374

Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial.

Auteurs : Vandeputte C, Bregni G, Gkolfakis P, Guiot T, Pretta A, Kehagias P, Senti C, Reina EA, Van Bogaert C, Deleporte A, Geboes K, Delaunoit T, Demolin G, Peeters M, DHondt L, Janssens J, Carrasco J, Holbrechts S, Goeminne JC, Vergauwe P, Van Laethem JL, Flamen P, Hendlisz A, Sclafani F
Année : 2021
Journal : Clin Colorectal Cancer
Volume : 20
Pages : 326-333